Rare Thyroid Therapeutics International AB

European Commission Approves Emcitate (Tiratricol) as First Treatment for MCT8 Deficiency

5 months ago

• The European Commission has granted marketing authorization for Emcitate (tiratricol), making it the first approved treatment for monocarboxylate transporter 8 (MCT8) deficiency in the EU. • The approval is based on data from Triac Trial I, the Erasmus University Medical Center Cohort Study, and preliminary results from Triac Trial II, demonstrating significant reductions in serum T3 concentrations. • Emcitate is indicated for treating peripheral thyrotoxicosis in MCT8 deficiency patients from birth, addressing symptoms like increased heart rate and muscle weakness. • Egetis Therapeutics anticipates initiating pricing and reimbursement discussions in Europe, with the first launch expected in the second quarter of 2025.